Report
Alex Morozov
EUR 100.00 For Business Accounts Only

Varian's 2Q Largely In Line; Maintaining Our Valuation

Varian's second-quarter results and full-year forecast on an organic currency-neutral basis remain in line with our expectations, and we maintain our fair value estimate of $105 per share. With shares rallying significantly over the past year, the stock trades at a moderate premium to our valuation. We maintain our wide moat rating.  
Varian's revised guidance for 2018 of 6%-9% on the revenue line was all due to more favorable currency, with healthy (albeit in-line) revenue growth through the fi...
Underlying
VARIAN MEDICAL SYSTEMS INC

Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions. The company's segments are: Oncology Systems, which designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, and treatments such as fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy and brachytherapy, as well as associated equipment; and Proton Solutions, which develops, designs, manufactures, sells and services products and systems for delivering proton therapy, for the treatment of cancer.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Alex Morozov

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch